



DISCOVERY LABORATORIES, INC.

Discovery Laboratories Schedules First Quarter Conference Call and Webcast

Doylestown, PA – May 13, 2003 – Discovery Laboratories, Inc. (Nasdaq: DSCO), a late-stage specialty pharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases, announces a conference call to be held Friday, May 16th at 8:45 AM EDT. Management will review progress through the First Quarter ended March 31, 2003.

This audio webcast will be available to shareholders and interested parties through a live broadcast on the Internet at <http://audioevent.mshow.com/104444/> and www.discoverylabs.com. It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. Please submit questions to dSCO@focuspartners.com. The Internet broadcast will be available for up to 30 days after the call at both website addresses.

About Discovery Laboratories, Inc.

Discovery Laboratories, Inc. is a specialty pharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases including Respiratory Distress Syndromes, Acute Lung Injury (ALI), asthma, Chronic Obstructive Pulmonary Disease (COPD), and upper airway disorders. Discovery's surfactant technology produces an engineered version of natural human lung surfactant that is designed to precisely mimic the essential properties of human lung surfactant. Discovery believes that through its surfactant technology, pulmonary surfactants have the potential, for the first time, to be developed into a series of respiratory therapies for hospitalized and ambulatory patients. Surfaxin, Discovery's lead product, is in three Phase 3 and two Phase 2 clinical trials for critical care patients with life-threatening respiratory disorders where there are few or no approved therapies available. Discovery's first aerosol surfactant product is positioned to enter clinical trials for hospital patients with severe asthma or acute lung injury. Discovery has a commercialization alliance with Quintiles Transnational Corp. and a strategic alliance with Laboratorios del Dr. Esteve S.A.

Interested parties can receive corporate updates by sending their email addresses to dSCO@focuspartners.com. More information about Discovery Laboratories is available on the Company's website at www.discoverylabs.com.

###